Stemcell, 100-1654, JNK-IN-8

Inhibit c-Jun N-terminal kinase (JNK) signaling with JNK-IN-8, an irreversible inhibitor of JNK1 (IC50 = 4.67 nM), JNK2 (IC50 = 18.7 nM), and JNK3 (IC50 = 0.98 nM). JNK-IN-8 inhibits JNK signaling by inhibiting the phosphorylation of the JNK substrate, c-Jun (Zhang et al. Chem Biol, 2012). JNKs are involved in regulating cell proliferation, differentiation, survival, and inflammation. Dysregulated JNK signaling has been associated with cancer as well as inflammatory and neurodegenerative diseases (Hammouda et al. Cells, 2020).

JNK-IN-8 has been used for:

CANCER RESEARCH

· Suppress colony formation and cell viability in human triple-negative breast cancer (TNBC) organoids and slow tumor growth in a mouse xenograft model (Soleimani et al. Mol Cancer Ther, 2022).

· Promote apoptosis and reduce clonogenic survival in human colorectal cancer organoids (Sun et al. Oncogene, 2021).

· Reduce tumor growth and regulatory T cell infiltration and increase infiltration of CD8+ T cells in a TNBC mouse model (Semba et al. J Natl Cancer Inst, 2022).

· Reduce cell viability of human and mouse B-lymphoblastic leukemia cells and slow leukemia progression in a mouse model (Xiao et al. J Hematol Oncol, 2020).